These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 17785018)

  • 21. Skin rash associated with atazanavir: report of three cases.
    Ouagari Z; Tubiana R; Mohand HA; Dominguez S; Duvivier C; Bricaire F; Katlama C; Caumes E
    AIDS; 2006 May; 20(8):1207-8. PubMed ID: 16691076
    [No Abstract]   [Full Text] [Related]  

  • 22. Atazanavir crystal nephropathy.
    Izzedine H; M'rad MB; Bardier A; Daudon M; Salmon D
    AIDS; 2007 Nov; 21(17):2357-8. PubMed ID: 18090291
    [No Abstract]   [Full Text] [Related]  

  • 23. Some PIs have greater impact than others on heart disease. Patients on atazanavir had less heart problems.
    AIDS Alert; 2006 Feb; 21(2):17-8. PubMed ID: 16562335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of atazanavir-based HAART regimen on the carotid intima-media thickness of HIV-infected persons: a comparative prospective cohort.
    de Saint-Martin L; Bressollette L; Perfezou P; Bellein V; Ansart S; Vallet S; Pasquier E
    AIDS; 2010 Nov; 24(18):2797-801. PubMed ID: 21063175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen.
    Colafigli M; Di Giambenedetto S; Bracciale L; Tamburrini E; Cauda R; De Luca A
    HIV Med; 2008 Mar; 9(3):172-9. PubMed ID: 18217998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can boosted atazanavir induce hyperlipotrophy?
    Dellamonica P
    J Infect; 2006 Jun; 52(6):e189-90. PubMed ID: 16239035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Long-term tolerance. Favorable lipid profile--favorable effect on development of lipodystrophy?].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():17. PubMed ID: 15373036
    [No Abstract]   [Full Text] [Related]  

  • 30. Acute hepatic cytolysis in an HIV-infected patient taking atazanavir.
    Eholié SP; Lacombe K; Serfaty L; Wendum D; Girard PM
    AIDS; 2004 Jul; 18(11):1610-1. PubMed ID: 15238786
    [No Abstract]   [Full Text] [Related]  

  • 31. Progression of Kaposi sarcoma associated with iatrogenic Cushing syndrome in a person with HIV/AIDS.
    Jinno S; Goshima C
    AIDS Read; 2008 Feb; 18(2):100-4. PubMed ID: 18333287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.
    Prescrire Int; 2009 Jun; 18(101):104. PubMed ID: 19637415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of an atazanivir associated grade 4 hyperbilirubinaemia with efavirenz.
    Kummer O; Mossdorf E; Battegay M; Elzi L; Bodmer M; Krähenbühl S; Haschke M
    Gut; 2007 Oct; 56(10):1477-8. PubMed ID: 17872579
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atazanavir: urolithiasis.
    Prescrire Int; 2014 Sep; 23(152):214. PubMed ID: 25325124
    [No Abstract]   [Full Text] [Related]  

  • 36. A comparison of different protease inhibitors on coronary heart disease risk.
    Coleman CI; White CM
    Conn Med; 2007 Jan; 71(1):15-7. PubMed ID: 17288101
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
    McRae M; Clay PG; Anderson PL; Glaros AG
    Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human placental transfer of atazanavir: a case report.
    Lechelt M; Lyons F; Clarke A; Magaya V; Issa R; de Ruiter A
    AIDS; 2006 Jan; 20(2):307. PubMed ID: 16511435
    [No Abstract]   [Full Text] [Related]  

  • 39. Pseudoaneurysm of the femoral artery in a HIV-infected man.
    Bongiovanni M; Pisacreta M; Ortu M; Tordato F; Codemo R; Gervasoni C; Gornati R; Trovati S; Piolini R; Chiesa E; Porretta T; Bini T
    Eur J Vasc Endovasc Surg; 2004 Oct; 28(4):451-3. PubMed ID: 15350573
    [No Abstract]   [Full Text] [Related]  

  • 40. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
    von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
    J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.